Completed PHASE2 INTERVENTIONAL NCT00004922

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Carcinoma of Unknown Primary Neuroendocrine Carcinoma Neuroendocrine Carcinoma of the Skin

Updated 5 times since 2017 Last updated: Jun 18, 2013 Started: Jun 30, 1999 Primary completion: Jun 30, 2002 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004922, this PHASE2 trial focuses on Carcinoma of Unknown Primary and Neuroendocrine Carcinoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States